Top 5 Safest Stocks To Invest In Right Now

&l;img class=&q;dam-image getty size-large wp-image-1125913011&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/1125913011/960×0.jpg?fit=scale&q; data-height=&q;640&q; data-width=&q;960&q;&g;

It&s;s awfully tempting. You see that money in your 401(k) plan account just sitting there. And you think of all the possible uses for it. Why not take a loan? You will pay it back — with interest!

Generally, that is a really bad idea. Here are the reasons why.

&l;strong&g;You will likely forfeit some company matching contributions&l;/strong&g;

Many individuals who borrow from their 401(k) accounts end up stopping or lowering their contributions while they are paying back their loans. This often results in the loss of 401(k) matching contributions when their contribution rates fall below the maximum matched percentage.

There is no better investment you can make than receiving free money in the form of company matching contributions. It is the safest, easiest way to earn 25%, 50% or 100% — depending upon your company&s;s matching percentage.

Top 5 Safest Stocks To Invest In Right Now: Akamai Technologies, Inc.(AKAM)

Advisors’ Opinion:

  • [By Garrett Baldwin]

    Click here to learn more.

    Stocks to Watch Today: GILD, AMZN, UAA, JPM, AAPL, NFLX
    Shares of Gilead Sciences Inc. (NASDAQ: GILD) fell 2.4% after the biotech giant announced disappointing results from a trial for a drug for chronic liver disease. In deal news, Amazon.com Inc. (NASDAQ: AMZN) will buy Wi-Fi/home router startup Eero for an undisclosed amount. The global e-commerce giant has been going on a smart-home acquisition streak. Last year, the firm bought video doorbell maker Ring for $1 billion. Eero is based in San Francisco and was founded in 2014. The firm makes mesh routers that aim to eliminate dead zones across a house or business location. Shares of Under Armour Inc. (NYSE: UAA) gained more than 2.2% after the company reported earnings before the bell. The sports apparel giant reported earnings per share of $0.09 (on an adjusted basis). That figure beat expectations of $0.04. The company’s sales were off about 6% in the fourth quarter but cited a big jump in foreign revenue. Last week, JPMorgan Chase & Co. (NYSE: JPM) released a report that recommended one of the deals of the decade. The bank has called for Apple Inc. (NASDAQ: AAPL) to buy streaming giant Netflix Inc. (NASDAQ: NFLX). This deal is a no-brainer in today’s market. We break down what a deal would look like, how it benefits both sides, and how it would be like rocket fuel for Apple stock. Here’s what you need to know. Look for earnings reports from Activision Blizzard Inc. (NASDAQ: ATVI), Aircastle Ltd. (NYSE: AYR), Akamai Technologies Inc. (NASDAQ: AKAM), Ares Capital Corp. (NASDAQ: ARCC), Denny’s Corp. (NASDAQ: DENN), Groupon Inc. (NASDAQ: GRPN), HubSpot Inc. (NASDAQ: HUBS), Molson Coors Brewing Co. (NYSE: TAP), Occidental Petroleum Corp. (NYSE: OXY), Shopify Inc. (NASDAQ: SHOP), and TripAdvisor Inc. (NASDAQ: TRIP).

    Follow Money Morning on Facebook, Twitter, and LinkedIn.

  • [By ]

    There could be a for sale sign planted in the ground at tech pioneer Akamai (AKAM) .

    “We’re a public company and our board, which is very professional and diligent, is always going to do the right thing for shareholders,” Akamai CEO Tom Leighton told TheStreet when asked if the company he co-founded in 1998 was for sale. While Leighton left the door open on a possible sale, he added that Akamai has strong prospects as a stand-alone company as well.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Akamai Technologies (AKAM)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By ]

    Meanwhile, Akamai’s (AKAM) CEO Tom Leighton didn’t shut the door to a potential sale of the company in an interview with me. Recent speculation on Wall Street is that Akamai would be an ideal fit for IBM (IBM) . 

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Akamai Technologies (AKAM)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Safest Stocks To Invest In Right Now: Dynavax Technologies Corporation(DVAX)

Advisors’ Opinion:

  • [By George Budwell]

    Shares of Dynavax Technologies (NASDAQ:DVAX), a vaccine and immuno-oncology specialist, dropped by 15.9% last month, according to data from S&P Global Market Intelligence. What sparked this sell-off?

  • [By Motley Fool Transcription]

    Dynavax Technologies Corporation (NASDAQ:DVAX) Q4 2018 Earnings Conference Call February 26, 2019, 4:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Logan Wallace]

    These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:

    Get Dynavax Technologies alerts:

    Dynavax Technologies Co. (DVAX) Receives Average Recommendation of “Buy” from Brokerages (americanbankingnews.com) Earnings per share (EPS) in the Spotlight – Dynavax Technologies Corporation (NASDAQ: DVAX) (stocksmarketcap.com) Is the Stock Safe to Invest? – Dynavax Technologies Corporation (NASDAQ:DVAX) (nasdaqjournal.com) Investor’s Watch List: Dynavax Technologies Corporation (DVAX) (nasdaqplace.com) You Need to Watch this stock? Dynavax Technologies Corporation (DVAX) (connectinginvestor.com)

    DVAX has been the topic of several analyst reports. Cantor Fitzgerald set a $27.00 price objective on Dynavax Technologies and gave the company a “buy” rating in a research note on Wednesday, May 16th. ValuEngine lowered Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Tuesday, May 1st. BidaskClub downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Sunday, April 22nd. Finally, JPMorgan Chase & Co. raised Dynavax Technologies from a “neutral” rating to an “overweight” rating and set a $25.00 target price on the stock in a report on Thursday, May 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. Dynavax Technologies currently has a consensus rating of “Buy” and an average target price of $24.67.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Keith Speights]

    For Dynavax Technologies Corporation (NASDAQ:DVAX), this old adage was spot-on. Between Jan. 1 and Nov. 8, 2017, the biotech stock increased more than fivefold. Investors eagerly awaited FDA approval of Dynavax’s Heplisav-B hepatitis B vaccine. After two unsuccessful attempts at approval, Heplisav-B finally won a green light from the FDA on Nov. 9. Since then, Dynavax’s share price has dropped 37%. 

Top 5 Safest Stocks To Invest In Right Now: Thor Industries Inc.(THO)

Advisors’ Opinion:

  • [By Keith Noonan, Rich Smith, and Tyler Crowe]

    For this roundtable, we asked three Motley Fool contributors to profile a company that has the makings of a long-term winner. Read on to see why they think that Thor Industries (NYSE:THO), Waste Management (NYSE:WM), and Activision Blizzard (NASDAQ:ATVI) are stocks that are poised to do big things over the next 20 years.

  • [By Asit Sharma]

    Leading recreational vehicle (RV) manufacturer Thor Industries, Inc. (NYSE:THO) reported a drop in revenue, as well as deterioration in several key financial metrics, in its fiscal fourth-quarter 2018 earnings report issued Thursday before the markets opened. The unexpectedly tepid performance jarred Thor shares, which traded down nearly 15% early in the trading session following the earnings release. Let’s review headline numbers below and uncover why shareholders found the report distasteful:

  • [By Ethan Ryder]

    Tahoe Resources (TSE:THO) (NASDAQ:TAHO) was downgraded by analysts at Beacon Securities from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday. They currently have a C$5.75 price target on the stock, down from their prior price target of C$10.00. Beacon Securities’ price objective would indicate a potential upside of 61.52% from the company’s current price.

  • [By Logan Wallace]

    Tahoe Resources (TSE:THO) (NASDAQ:TAHO) – Equities research analysts at National Bank Financial reduced their FY2018 earnings estimates for shares of Tahoe Resources in a research report issued on Monday, April 9th. National Bank Financial analyst M. Parkin now forecasts that the company will earn $0.29 per share for the year, down from their prior forecast of $0.35. National Bank Financial currently has a “Sector Perform” rating and a $8.00 price objective on the stock.

  • [By Ethan Ryder]

    First Allied Advisory Services Inc. lowered its position in Thor Industries, Inc. (NYSE:THO) by 20.5% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 4,104 shares of the construction company’s stock after selling 1,060 shares during the period. First Allied Advisory Services Inc.’s holdings in Thor Industries were worth $401,000 at the end of the most recent quarter.

Top 5 Safest Stocks To Invest In Right Now: American River Bankshares(AMRB)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on American River Bankshares (AMRB)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on American River Bankshares (AMRB)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    American River Bankshares (NASDAQ:AMRB) was downgraded by investment analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.

Top 5 Safest Stocks To Invest In Right Now: Curis, Inc.(CRIS)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) rose 65.5 percent to $179.50 in pre-market trading. Madrigal Pharma disclosed that MGL-3196 achieved liver biopsy endpoints in patients with NASH at 36 weeks in Phase 2 trial.
    Viking Therapeutics, Inc. (NASDAQ: VKTX) rose 34.8 percent to $6.70 in pre-market trading after falling 4.42 percent on Wednesday.
    vTv Therapeutics Inc. (NASDAQ: VTVT) shares rose 31.5 percent to $2.19 in pre-market trading after the company reported a licensing deal with Newsoara Biopharma to rights for vTv's PDE4 Inhibitor in China and other Pacific Rim territories.
    Curis, Inc. (NASDAQ: CRIS) shares rose 27.2 percent to $2.90 in pre-market trading after the company reported FDA Fast Track designation for CUDC-907 development in patients with relapse, refractory diffuse large B-cell lymphoma.
    Kitov Pharma Ltd (NASDAQ: KTOV) rose 16.7 percent to $2.51 in pre-market trading.
    Tilly's, Inc. (NYSE: TLYS) rose 14.7 percent to $14.00 in pre-market trading as the company reported better-than-expected earnings for its first quarter and issued a strong Q2 outlook.
    Express, Inc. (NYSE: EXPR) rose 14.3 percent to $10.49 in pre-market trading after the company reported better-than-expected results for its first quarter.
    NGL Energy Partners LP (NYSE: NGL) rose 12.8 percent to $12.10 in pre-market trading after reporting Q4 earnings beat.
    J.Jill, Inc. (NYSE: JILL) rose 11.3 percent to $6.90 in pre-market trading after the company posted upbeat quarterly earnings.
    TapImmune, Inc. (NASDAQ: TPIV) shares rose 10 percent to $5.60 in pre-market trading after climbing 24.15 percent on Wednesday.
    Frontline Ltd. (NYSE: FRO) rose 9.8 percent to $5.74 in pre-market trading after Q1 results beat estimates.
    Tech Data Corporation (NASDAQ: TECD) rose 8.8 percent to $89.65 in pre-market trading following better-than-expected Q1 earnings.
    TransEnterix, Inc. (NYSE: TRXC) shares rose 7.1 percent to $3.65 in pre-market tra
  • [By Lisa Levin] Gainers
    Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) jumped 124.8 percent to $243.725 in reaction to an encouraging Phase 2 clinical trial update. The clinical-stage biopharmaceutical company said its liver-directed, thyroid hormone receptor called MGL-3196 showed a statistical significance in the primary endpoint of lowering liver fat at 12 weeks and also 36 weeks.
    Viking Therapeutics, Inc. (NASDAQ: VKTX) gained 63.4 percent to $8.12 after falling 4.42 percent on Wednesday.
    Takung Art Co., Ltd. (NYSE: TKAT) rose 43.3 percent to $2.9094
    vTv Therapeutics Inc. (NASDAQ: VTVT) shares climbed 29.7 percent to $2.16 after the company reported a licensing deal with Newsoara Biopharma to rights for vTv's PDE4 Inhibitor in China and other Pacific Rim territories.
    Akers Biosciences, Inc. (NASDAQ: AKER) gained 26.2 percent to $0.4109. The developer of rapid health information technologies said Wednesday afternoon it was granted a 180-day extension from the Nasdaq Stock Market to meet the requirement of a minimum $1.00 per share closing bid price for 10 straight days.
    Genprex, Inc. (NASDAQ: GNPX) rose 22.2 percent to $11.6254. Genprex reported engagement of WIRB-Copernicus Group to provide clinical trial services to support Oncoprex clinical trial program.
    J.Jill, Inc. (NYSE: JILL) gained 21 percent to $7.506 after the company posted upbeat quarterly earnings.
    Urban One, Inc. (NASDAQ: UONE) gained 19.7 percent to $3.95 after rising 78.38 percent on Wednesday.
    TapImmune, Inc. (NASDAQ: TPIV) shares gained 18.5 percent to $6.03 after climbing 24.15 percent on Wednesday.
    Kirkland's, Inc. (NASDAQ: KIRK) rose 17.3 percent to $12.95 after reporting upbeat Q1 results.
    CymaBay Therapeutics, Inc. (NASDAQ: CBAY) shares gained 15.1 percent to $13.210.
    The Brink's Company (NYSE: BCO) climbed 14.2 percent to $77.875 as the company announced plans to acquire Dunbar Armored for $520 million in cash.
    Keysight Technologies, Inc. (NYSE: KEY
  • [By Lisa Levin] Gainers
    Sigma Labs, Inc. (NASDAQ: SGLB) shares rose 90.9 percent to $2.52. Sigma Labs demonstrated proof of concept for closed loop quality control during metal additive manufacturing.
    Oragenics, Inc. (NYSE: OGEN) shares surged 58.4 percent to $1.9005 after the company’s AG013 for oral mucositis in head and neck cancer patients showed favorable safety profile in mid-stage OM study.
    Dick's Sporting Goods, Inc. (NYSE: DKS) shares climbed 23.2 percent to $37.5370 after the company reported upbeat Q1 earnings and raised FY18 earnings outlook.
    Summer Infant, Inc. (NASDAQ: SUMR) rose 21.9 percent to $1.17 after announcing commitment for $60 million credit facility from Bank of America and $17.5 million term loan from Pathlight Capital.
    TapImmune, Inc. (NASDAQ: TPIV) jumped 18.8 percent to $4.87. WBB Securities upgraded TapImmune from Speculative Buy to Buy.
    Movado Group, Inc. (NYSE: MOV) gained 17.2 percent to $49.45 after the company reported better-than-expected Q1 results and raised its guidance.
    ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) jumped 16.2 percent to $7.96. BTIG Research initiated coverage on ASLAN Pharmaceuticals with a Buy rating.
    Legacy Reserves LP (NASDAQ: LGCY) rose 15.5 percent to $5.6011.
    InspireMD, Inc. (NYSE: NSPR) gained 13.3 percent to $1.36 following PR announcing sustained benefit of CGuard EPS.
    Immutep Limited (NASDAQ: IMMP) shares climbed 13.2 percent to $2.7724 after the company reported new data from its ongoing TACTI-mel Phase I trial, which evaluated the combination of eftilagimod alpha, its lead compound, with Merck & Co., Inc. (NYSE: MRK)'s Keytruda in unresectable or metastatic melanoma patients, who have had a suboptimal response or had disease progression with keytruda monotherapy..
    SpartanNash Co (NASDAQ: SPTN) rose 12.2 percent to $21.20 after the company reported upbeat earnings for its first quarter on Tuesday.
    Amtech Systems, Inc. (NASDAQ: ASYS) rose 12.1 percent to
  • [By Brian Feroldi]

    Curis, Inc. (NASDAQ:CRIS), a beaten up clinical-stage biopharma focused on cancer, jumped 23% as of 2:43 p.m. EDT on Thursday in response to announcing that one of its key compounds has received Food and Drug Administration (FDA) Fast Track designation.

  • [By Joseph Griffin]

    Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:

    Get Curis alerts:

    $2.41 Million in Sales Expected for Curis, Inc. (CRIS) This Quarter (americanbankingnews.com) Curis Stock Scheduled to Reverse Split on Wednesday, May 30th (CRIS) (americanbankingnews.com) Zacks: Analysts Expect Curis, Inc. (CRIS) to Post -$0.09 Earnings Per Share (americanbankingnews.com) Curis Expands Senior Management Expertise with Appointment of Robert Martell, M.D., Ph.D., as Head of Research and Development (finance.yahoo.com) Is Curis, Inc. (CRIS) In Search of Footing? (nmsunews.com)

    Shares of Curis stock traded up $0.01 on Monday, hitting $0.45. The company had a trading volume of 1,290,968 shares, compared to its average volume of 1,462,753. The stock has a market capitalization of $74.57 million, a PE ratio of -1.25 and a beta of 1.29. Curis has a twelve month low of $0.41 and a twelve month high of $2.27. The company has a quick ratio of 3.60, a current ratio of 3.60 and a debt-to-equity ratio of 2.24.

  • [By Lisa Levin] Gainers
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) rose 18.2 percent to $4.55 in pre-market trading after the company declared a $0.70 per share special dividend.
    Co-Diagnostics, Inc. (NASDAQ: CODX) rose 11.7 percent to $3.24 in pre-market trading after falling 13.17 percent on Thursday. Co-Diagnostics reported its participation in a research project with the Stanford University.
    Abercrombie & Fitch Co. (NYSE: ANF) shares rose 8.6 percent to $25.95 in pre-market trading after the company posted upbeat Q1 results.
    Zuora, Inc. (NYSE: ZUO) shares rose 8 percent to $23.95 in pre-market trading after the company reported upbeat Q1 earnings and issued strong outlook.
    Lululemon Athletica Inc. (NASDAQ: LULU) shares rose 7.8 percent to $113.25 in pre-market trading after the company reported better-than-expected results for its first quarter. The company also raised its FY18 earnings and sales guidance.
    OPKO Health, Inc. (NYSE: OPK) rose 5.7 percent to $4.10 in pre-market trading.
    Lannett Company, Inc. (NYSE: LCI) rose 5.5 percent to $17.45 in pre-market trading following the FDA approval for Levofloxacin Oral Solution.
    Eversource Energy (NYSE: ES) shares rose 5 percent to $59.8 in pre-market trading.
    VMware, Inc. (NYSE: VMW) rose 4.6 percent to $143.74 in pre-market trading as the company reported stronger-than-expected results for its first quarter on Thursday.
    Energy Transfer Partners, L.P. (NYSE: ETP) rose 4.3 percent to $19.80 in pre-market trading after the company reported the Federal Energy Regulatory Commission approval to place Rover pipeline’s full Mainline B into service.
    T2 Biosystems, Inc. (NASDAQ: TTOO) rose 4.3 percent to $7.73 in pre-market trading after declining 4.26 percent on Thursday.
    Curis, Inc. (NASDAQ: CRIS) rose 4.3 percent to $2.90 in pre-market trading after jumping 21.93 percent on Thursday.
    Sasol Limited (NYSE: SSL) rose 4.2 percent to $37.91 in pre-market trading.
    Nucor Corporatio

Leave a Reply

Your email address will not be published. Required fields are marked *